Evidence map›Paper›PMID 28827889›Full record

ArticleComputational statistics & data analysis2017

A parametric model to estimate the proportion from true null using a distribution for p-values.

Chang Yu, Daniel Zelterman

Abstract read
In one paragraph

Article in Computational statistics & data analysis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Null-free False Discovery Rate Control Using Decoy Permutations.Acta mathematicae applicatae Sinica (English series) · 2022
    Article
  2. A parametric meta-analysis.Statistics in medicine · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chang YuDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, U.S.A.
Daniel ZeltermanDepartment of Biostatistics, Yale University, New Haven, CT 06520, U.S.A.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MARCUS W BOSENBERG · 1985 to 2026
$85.0M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Kurt A Schalper · 2015 to 2026
$31.1M
Sex Hormones in Pulmonary Arterial HypertensionP01HL108800 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LOYD, JAMES E · 2012 to 2021
$22.0M
Research Project CoreP01NS047399 · NINDS · YALE UNIVERSITY · PI LA MOTTE, ROBERT H · 2004 to 2013
$11.0M
Oncometabolites, DNA Repair, and CancerR01ES005775 · NIEHS · YALE UNIVERSITY · PI PETER M GLAZER · 1998 to 2026
$8.0M
Caveolar Defects Underlie the Genetic Origins of PAHR01HL111259 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KENWORTHY, ANNE K, LOYD, JAMES E · 2012 to 2016
$3.5M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)KL2TR000446 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$2.8M
Personalized Prevention of Colorectal CancerR01CA149633 · NCI · VANDERBILT UNIVERSITY · PI DAI, QI, YU, CHANG · 2010 to 2014
$2.0M
Cell-Penetrating Anti-DNA Antibody for Radiosensitization and Cancer TherapyR01CA168733 · NCI · YALE UNIVERSITY · PI GLAZER, PETER M · 2013 to 2017
$1.7M
Real-world patient responsiveness & safety of long-acting beta agonists in asthmaR01HS022093 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WU, PINGSHENG · 2013 to 2013
$1.6M
AHRQ HHS R01 HS022093NCATS NIH HHS KL2 TR000446NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA196530NCI NIH HHS R01 CA149633NCI NIH HHS R01 CA168733NCI NIH HHS R01 CA177719NHLBI NIH HHS P01 HL108800NHLBI NIH HHS R01 HL111259NHLBI NIH HHS R21 HL123829NHLBI NIH HHS R21 HL129020NIEHS NIH HHS R01 ES005775NINDS NIH HHS P01 NS047399
6 · The paper itself

Abstract

Microarray studies generate a large number of p-values from many gene expression comparisons. The estimate of the proportion of the p-values sampled from the null hypothesis draws broad interest. The two-component mixture model is often used to estimate this proportion. If the data are generated under the null hypothesis, the p-values follow the uniform distribution. What is the distribution of p-values when data are sampled from the alternative hypothesis? The distribution is derived for the chi-squared test. Then this distribution is used to estimate the proportion of p-values sampled from the null hypothesis in a parametric framework. Simulation studies are conducted to evaluate its performance in comparison with five recent methods. Even in scenarios with clusters of correlated p-values and a multicomponent mixture or a continuous mixture in the alternative, the new method performs robustly. The methods are demonstrated through an analysis of a real microarray dataset.

Indexed as

distribution of p-valuesmicroarray studiesmixture modelproportion from the null hypothesis

Identifiers

PMID28827889
PMCPMC5562234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.